EUVIMEDEUVIMED entdecken
Crossref

Antidiabetic Bioactive Peptides from A2 Milk Fermented by Lacticaseibacillus rhamnosus: Enzyme Inhibition and Docking Insights

Dandy Yusuf, Rini Handayani, Sulistiani, Fera Roswita Dewi, Lutfi Anggadhania, Syafri Izzat Abidiy, A.A. Muhammad Nur Kasman

Applied food biotechnology · 06.09.2025

DOI: 10.22037/afb.v12i1.48611 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Applied food biotechnology, erschienen am 06.09.2025. Verfasst von Dandy Yusuf und 6 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective: Diabetes mellitus is a long-term disorder characterized by the body’s inability to regulate excessive blood glucose levels. The incidence of diabetes mellitus worldwide has significantly increased in recent decades. In addition to careful regulation of food quantities, improving food quality through the consumption of functional foods that do not trigger glucose spikes is also recommended. Accordingly, the aim of this research is to determine the potency of antidiabetic functional food derived from the fermentation of A2 cow's milk with higher β-casein content using Lacticaseibacillus rhamnosus RAL43. Material and Methods: This study involved in vitro assays to test the inhibitory activity against diabetes-related enzymes, namely α-glucosidase, α-amylase, and dipeptidyl peptidase-4 (DPP4), followed by molecular docking simulations. Results and Conclusion: The results of the study showed inhibitory activity against enzymes that trigger blood glucose spikes, namely 66.35% against α-glucosidase, 68.87% against α-amylase, and 10.69% against DPP4. The results of the analysis showed an increase in the quantity of peptides after fermentation, along with the results of the analysis of L. rhamnosus RAL43 which showed high proteolytic activity during fermentation. After ultrafiltration, it was found that the greatest inhibitory activity came from protein with molecular weight (MW) larger than 10 kDa. The amino acid sequencing process with high-resolution liquid chromatography-mass spectrometry then showed bioactive peptides, including VLVLDTDYK which was previously reported to show DPP4 inhibitory activity, along with many other peptides that display various specific bioactivities. The VLVLDTDYK peptide fragment was successfully docked and positioned in the DPP4 molecule through molecular docking simulations. This study concluded that A2 milk can be a functional substrate to produce specific bioactive peptides that inhibit enzymes that trigger blood glucose spikes that have a negative impact on diabetes. L. rhamnosus RAL43 can be developed as a proteolytic isolate and starter culture to produce foods with functional properties that can aid in blood glucose regulation. Keywords: Bioactive Peptides, A2 Milk, Antidiabetic, Molecular Docking Introduction Diabetes mellitus (DM) has emerged as a significant global health issue. It is a persistent condition marked by increased blood glucose levels, typically above 180 mg.dL-1. Under normal circumstances, the hormone insulin regulates blood glucose levels by converting glucose into energy for cells. However, in individuals with diabetes, the body either does not produce enough insulin or cannot use it effectively to control blood glucose levels. According to data released by the International Diabetes Federation, Type 2 Diabetes Mellitus (T2DM) is the most common form globally and continues to increase significantly each year. The primary causes of T2DM include being overweight and obese, often due to an unbalanced diet and lack of physical activity. T2DM typically does not exhibit critical symptoms in its early stages, causing many individuals to remain unaware of their condition. Chatterjee et al. [1] and Antar et al. [2] identified a prediabetic phase that precedes full-blown diabetes. With proper prevention and management during the prediabetic phase, T2DM can still be avoided. In principle, individuals with T2DM must consistently avoid high blood glucose levels, particularly postprandial spikes [1,2]. Besides careful control of dietary quantity, improving diet quality through the consumption of functional foods that do not trigger glucose spikes is also recommended. Foods or beverages that offer health benefits are referred to as functional foods. Antidiabetic functional foods have been reported to originate from fermented products containing probiotics and/or bioactive compounds that inhibit digestive enzymes involved in carbohydrate breakdown into glucose, including α-amylase, α-glucosidase, and dipeptidyl peptidase-4 (DPP4) [3-5]. Functional foods with antidia-betic activity are considered a promising alternative for managing T2DM without the side effects often associated with pharmaceutical treatments [6]. Digestive enzyme inhibitors operate through various mechanisms. The enzymes α-amylase and α-glucosidase break down complex carbohydrates into simple sugars for absorption in the intestines. Inhibiting these enzymes helps slow glucose absorption and prevents postprandial blood glucose spikes [7]. Meanwhile, the DPP4 enzyme plays a critical role in blood glucose regulation by degrading incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). This degradation can suppress insulin secretion and burden the pancreas. DPP4 inhibitors are thought to prevent incretin breakdown, thereby maintaining normal glucose levels and enhancing insulin sensitivity [8]. Enzyme inhibitors targeting α-amylase, α-glucosidase, and DPP4 have been reported in the form of short-chain peptide fragments produced through proteolytic processes, either via enzy-matic hydrolysis or microbial fermentation [9-11]. These peptide-based inhibitors are thought to function as competitive inhibitors by attaching to the enzyme’s active site, preventing substrate binding, and thereby slowing down the buildup of glucose in the blood [12]. Other reported types of enzyme inhibitors include flavonoids, terpenoids, phenolic acids, tannins, alkaloids, and xanthones [10,13]. However, this study will focus specifically on exploring peptide-based inhibitors produced through fermentation by lactic acid bacteria (LAB) isolates. Once the bioactivity data are obtained and the peptide sequences with potential inhibitory effects are identified, the next step is to perform molecular docking. Molecular docking is a crucial and efficient method for exploring the potential bioactivity of inhibitory peptides. It provides a strong scientific basis prior to biological testing, accelerates the screening process, and helps focus the research on the most promising peptide candidates [14]. This computational approach allows for the modeling and prediction of molec-ular interactions between candidate peptides and target enzymes. In this study, molecular docking is used to generate preliminary data supporting the hypothesis that the identified peptides may possess inhibitory activity against the target enzyme. Fermented dairy products using LAB have been reported to exhibit antidiabetic potential [3,15,16]. Although not classified as therapeutic drugs, these products are considered effective as functional foods for diabetes preven-tion and management [7,17]. LAB have a significant advantage due to their proteolytic activity, enabling the breakdown of proteins into short-chain peptides. Dairy products fermented with LAB are well recognized as rich sources of bioactive peptides that exhibit antidiabetic, antioxidant, antihypertensive, cholesterol-lowering, and various other functional effects [18-20]. In this study, three lactic acid bacteria isolates (Lacticaseibacillus (L.) rhamnosus RAL27, Limosilactobacillus fermentum RAL29, and L. rhamnosus RAL43) previously isolated from Indonesian kefir grains [21], will be used to ferment A2-type cow’s milk. In recent years, A2 milk has been introduced. This type of milk was first commercialized in New Zealand and has since been marketed in several countries [22]. The main differences between A1 and A2 milk lie in the amino acid composition and β-casein. A1 β-casein contains histidine at position 67, while A2 β-casein contains proline at the same position [23]. These subtle differences can affect human digestion and metabolism. Some studies suggest that A1 milk may be associated with gastrointestinal discomfort and symptoms similar to lactose intolerance. A study by Choi et al. [24] found that participants consuming A1 milk reported more bloating and abdominal pain compared to those consuming A2 milk. The release of β-casomorphin-7 (BCM-7), a peptide derived from A1 β-casein during digestion, is thought to contribute to these symptoms. Some epidemiological studies suggest that A1 milk may be correlated with an increased risk of heart disease due to its inflammatory effects [23]. Conver-sely, A2 milk may offer cardioprotective effects, although further clinical trials are needed to validate these findings. A possible link between A1 milk consumption and the onset of type 1 diabetes has been proposed. A study by Kay et al. [23] suggests that early exposure to A1 milk may be associated with an increased risk of developing autoimmune conditions, possibly due to an immune response triggered by β-casomorphin-7 (BCM-7). With increasing health and wellness awareness, consumer demand for A2 milk has increased significantly. Many dairy companies have begun marketing A2 milk as a healthier alternative to A1 milk, capitalizing on its perceived benefits. This shift reflects a broader trend toward personalized nutrition and the importance of understanding genetic variation in food choices.The fermentation of A2 milk is expected to generate a new and unique peptide profile. Digestive conditions can influence the stability and absorption of peptides produced by A2 milk fermentation. Many peptides are biodegradable, so only peptides of a certain size or structure are retained. Smaller peptides may persist, while larger ones tend to break into fragments. Some bioactive peptides (e.g., DPP4 or α-glucosidase inhibitors) have been shown to remain active even after simulated in vitro digestion, but their persistence varies depending on sequence and structure [7,25]. However, not all peptides identified in vitro will persist into the systemic circulation. However, local activity in, for example, (α-glucosidase inhibition) is expected to remain relevant, even if the peptide is not absorbed in large quantities from the gut. Therefore, this s

Schlagwörter

bioactive peptidesA2 milkLactobacillus rhamnosusfermented milkantidiabetic activityα-glucosidase inhibitionα-amylase inhibitionDPP-4 inhibitionproteolysisfunctional foods

Zitieren

APA

Yusuf, D., Handayani, R., Sulistiani, Dewi, F. R., Anggadhania, L., Abidiy, S. I., & Kasman, A. M. N. (2025). Antidiabetic Bioactive Peptides from A2 Milk Fermented by Lacticaseibacillus rhamnosus: Enzyme Inhibition and Docking Insights. Applied food biotechnology. https://doi.org/10.22037/afb.v12i1.48611

Vancouver

Yusuf D, Handayani R, Sulistiani, Dewi FR, Anggadhania L, Abidiy SI, et al. Antidiabetic Bioactive Peptides from A2 Milk Fermented by Lacticaseibacillus rhamnosus: Enzyme Inhibition and Docking Insights. Applied food biotechnology. 2025. doi:10.22037/afb.v12i1.48611

BibTeX
@article{Yusuf2025,
  author = {Yusuf, Dandy and Handayani, Rini and Sulistiani and Dewi, Fera Roswita and Anggadhania, Lutfi and Abidiy, Syafri Izzat and Kasman, A.A. Muhammad Nur},
  title = {Antidiabetic Bioactive Peptides from A2 Milk Fermented by Lacticaseibacillus rhamnosus: Enzyme Inhibition and Docking Insights},
  journal = {Applied food biotechnology},
  year = {2025},
  doi = {10.22037/afb.v12i1.48611}
}
Kostenlos starten →